Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses

• Published in: Leukemia Vol. 38; no. 4; pp. 751 - 761
• Main Authors: Severens, Jeppe F., Karakaslar, E. Onur, van der Reijden, Bert A., Sánchez-López, Elena, van den Berg, Redmar R., Halkes, Constantijn J. M., van Balen, Peter, Veelken, Hendrik, Reinders, Marcel J. T., Griffioen, Marieke, van den Akker, Erik B.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2024; Nature Publishing Group
• Subjects: 631/67/1990/283/1897; 631/67/69; 692/699/67/1059/602; Abnormalities; Acute myeloid leukemia; Arrests; Cancer Research; Cell differentiation; Classification; Cluster analysis; Clustering; Critical Care Medicine; Datasets; Differentiation; Gene expression; Gene mapping; Genetic abnormalities; Hematology; Heterogeneity; Intensive; Internal Medicine; Leukemia; Medicine; Medicine & Public Health; Myelodysplastic syndrome; Myelodysplastic syndromes; Oncology; Patients; Phenotyping; Survival analysis; Transcriptomics
• ISSN: 0887-6924; 1476-5551; 1476-5551
• DOI: 10.1038/s41375-024-02137-6

Subtyping of acute myeloid leukaemia (AML) is predominantly based on recurrent genetic abnormalities, but recent literature indicates that transcriptomic phenotyping holds immense potential to further refine AML classification. Here we integrated five AML transcriptomic datasets with corresponding genetic information to provide an overview ( n  = 1224) of the transcriptomic AML landscape. Consensus clustering identified 17 robust patient clusters which improved identification of CEBPA -mutated patients with favourable outcomes, and uncovered transcriptomic subtypes for KMT2A rearrangements (2), NPM1 mutations (5), and AML with myelodysplasia-related changes (AML-MRC) (5). Transcriptomic subtypes of KMT2A , NPM1 and AML-MRC showed distinct mutational profiles, cell type differentiation arrests and immune properties, suggesting differences in underlying disease biology. Moreover, our transcriptomic clusters show differences in ex-vivo drug responses, even when corrected for differentiation arrest and superiorly capture differences in drug response compared to genetic classification. In conclusion, our findings underscore the importance of transcriptomics in AML subtyping and offer a basis for future research and personalised treatment strategies. Our transcriptomic compendium is publicly available and we supply an R package to project clusters to new transcriptomic studies.